Abstract:Abstract Purpose: We evaluated the performance of the longitudinal-radiomics of multi-parametric magnetic resonance imaging (MRI), developed and validated based on a multicenter dataset adopting a radiomic strategy, for prediction of treatment response to neoadjuvant chemotherapy (NAC) in breast cancer. Methods and materials: We analyzed clinical and pathological data of patients with breast cancer and compared machine-learning classification algorithms in predicting treatment response following NAC from four hospitals (primary cohort and external validation cohort 1-3) between July 2015 and December 2021. Patients were monitored with MRI before (pretreatment) and after (mid-treatment) three or four cycles of NAC. Longitudinal-radiomics analysis was performed at pre- and mid-treatment dynamic contrast-enhanced, T2-weighted imaging, and diffusion-weighted imaging mapping by using 3D Slicer software. Radiomics features were extracted from original and filtered images using PyRadiomics (V3.0.1) filtered images were generated using Laplacian of Gaussian and wavelet filters. The stacking strategy including LR, LDA and SVM (radial basis function) were used to combined the results of the base models, and gave a secondary prediction result. Results: In total, 1048 cases were enrolled in the study. In identifying the residual cancer burden (RCB) 0 v.s. RCB 1-3, longitudinal-radiomic models achieved the highest area under the receiver operating characteristic curve (AUC) of 0.909 and 0.893 in the training and test sets. The accuracies of the stacking-SVM classifier were 84.3% (86/102), 75.6% (205/271) and 77.9% (265/340) in the external validation set. In identifying the RCB 3 v.s. RCB 0-2, longitudinal-radiomic models achieved the highest AUC of 0.981 and 0.923 in the training and test sets. In the external validation set, the performance was with accuracy=91.2%-92.2%. The cascade model also stratified 78.9%, 69.1% and 76.1% of the RCB 1-2 patients into RCB 1-2 prediction group to receive suitable NAC and feasible breast-conserving surgery. Our findings showed high predictive ability and reproducibility across multicenter dataset. By two-step prediction results of cascade models, the patient could be assigned to one of the three groups corresponding to three RCB status: RCB 0, RCB 1-2, or RCB 3. In this way, using the cascade models, some of RCB 3 patients may allow treatment to be tailored for optimal outcomes. RCB 0 and RCB 1-2 groups could receive suitable NAC and feasible breast-conserving surgery. Conclusion: In conclusion, our study had good predictive ability for RCB assessment, which could help clinicians guide individualized treatment options for breast cancer patients in NAC. The application of stacking cascade model may have the potential to further reduce unnecessary NAC and economic costs associated with current breast cancer management. Figure 1. The flowchart of the study. This was a multicenter study with patients retrospectively enrolled from four medical centers in different cities of China. Pretreatment and midtreatment multi-parametric MRI (DCE, T2WI, and DWI) and clinical information were proposed to predict treatment response to NAC in patients with primary invasive breast cancer. The data from Foshan was used as the primary cohort (PC), and the other three data sets were used as independent validation cohorts (VC). This study included radiomic feature engineering, model building, model comparison and clinical application. Figure 1. The flowchart of the study. This was a multicenter study with patients retrospectively enrolled from four medical centers in different cities of China. Pretreatment and midtreatment multi-parametric MRI (DCE, T2WI, and DWI) and clinical information were proposed to predict treatment response to NAC in patients with primary invasive breast cancer. The data from Foshan was used as the primary cohort (PC), and the other three data sets were used as independent validation cohorts (VC). This study included radiomic feature engineering, model building, model comparison and clinical application. Figure 2. ROC curves among different radiomic signatures and among different models in identifying the RCB 0 vs RCB 1-3. RCB, residual cancer burden; ROC, receiver operating characteristic; SVM, support vector machine; RF, random forest; MLP, multilayer perceptron; LR, logistic regression. Figure 2. ROC curves among different radiomic signatures and among different models in identifying the RCB 0 vs RCB 1-3. RCB, residual cancer burden; ROC, receiver operating characteristic; SVM, support vector machine; RF, random forest; MLP, multilayer perceptron; LR, logistic regression. Figure 3. ROC curves among different radiomic signatures and among different models in identifying the RCB 3 vs RCB 0-2. RCB, residual cancer burden; ROC, receiver operating characteristic; SVM, support vector machine; RF, random forest; MLP, multilayer perceptron; LR, logistic regression. Figure 3. ROC curves among different radiomic signatures and among different models in identifying the RCB 3 vs RCB 0-2. RCB, residual cancer burden; ROC, receiver operating characteristic; SVM, support vector machine; RF, random forest; MLP, multilayer perceptron; LR, logistic regression. Citation Format: wei li, Yuhong huang, teng zhu, zhiyong wu, ying lin, guolin ye, Kun Wang. Multiparametric MRI-based Longitudinal-radiomics Analysis for Early Prediction of Treatment Response of Breast Cancers to Neoadjuvant Chemotherapy: A Multicenter Study [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-01-19.

Time-Dependent Diffusion MRI Helps Predict Molecular Subtypes and Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer

Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models

Predicting Pathologic Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer Using Multiparametric MRI

Multiparametric MRI radiomics fusion for predicting the response and shrinkage pattern to neoadjuvant chemotherapy in breast cancer

Diffusion-Weighted MRI in Predicting the Efficacy of Neoadjuvant Chemotherapy of Breast Cancer.

The longitudinal changes in multiparametric MRI during neoadjuvant chemotherapy can predict treatment response early in patients with HER2-positive breast cancer

Abstract P6-01-19: Multiparametric MRI-based Longitudinal-radiomics Analysis for Early Prediction of Treatment Response of Breast Cancers to Neoadjuvant Chemotherapy: A Multicenter Study

Radiomic Analysis of DCE-MRI for Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.

Breast Cancer: Multi-b-Value Diffusion Weighted Habitat Imaging in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy

Radiomics Analysis of Multi-Phase DCE-MRI in Predicting Tumor Response to Neoadjuvant Therapy in Breast Cancer

Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer

The contrast‐free diffusion MRI multiple index for the early prediction of pathological response to neoadjuvant chemotherapy in breast cancer

Time-Dependent Diffusion MRI for Quantitative Microstructural Mapping of Prostate Cancer

Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge

Multiparametric MRI-based radiomics combined with pathomics features for prediction of the efficacy of neoadjuvant chemotherapy in breast cancer

Abstract P6-01-35: A Pre-operative Dynamic Contrast Enhanced MRI-Based Radiomics Models as Predictors of Treatment Response after Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer Patients

Abstract 5980: Identification of pre-treatment tumor habitats for the prediction of neoadjuvant therapy response in triple negative breast cancer

Radiomics of Tumor Heterogeneity in Longitudinal Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer

A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer

Abstract P6-01-06: Multi-Parametric MRI-Based Radiomics Models from Tumor and Peritumoral Regions as Potential Predictors of Treatment Response to Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer Patients

Diffusion-time Dependent Diffusion MRI: Effect of Diffusion-Time on Microstructural Mapping and Prediction of Prognostic Features in Breast Cancer